Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rangering i aksjer #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Aksjekurs
$0.1559364
Sist synkronisert: 2026-09-18
Markedsverdi
$195.17K
Endring (1 dag)
6.60%
Endring (1 år)
-30.91%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategori

Healthcare
Inntekter for Fusion Antibodies plc (FAB)
Inntekter i Sep 2025 TTM: $2.15M
Ifølge de nyeste økonomiske rapportene til Fusion Antibodies plc er selskapets nåværende inntekter (TTM) $2.15M. I 2024 hadde selskapet inntekter på $1.43M en nedgang sammenlignet med inntektene i 2023, som var $3.58M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Fusion Antibodies plc fra 2013 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 588,305.51%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 280,545.95%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 103,744.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 733,726.73%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH